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Abstract
Thrombocytosis portends adverse prognostic significance in many types of
cancers including ovarian and lung carcinoma. In this study, we determined the
prevalence and prognostic significance of thrombocytosis (defined as platelet
count in excess of 400 K/μl) in patients with colorectal cancer. We performed a
retrospective analysis of 310 consecutive patients diagnosed at our institution
between 2004 and 2013. The patients (48.7% male and 51.3% female) had a
mean age of 69.9 years (+/- 12.7 years) at diagnosis. Thrombocytosis was
found in a total of 25 patients, with a higher incidence in those with stage III and
IV disease (14.4% of patients). Although the mean platelet count increased with
the depth of tumor invasion (pT), its values remained within normal limits in the
whole patient cohort. No patient with stage I cancer (n=57) had elevated
platelet count at diagnosis. By contrast, five of the 78 patients (6.4%) with stage
II cancer showed thrombocytosis, and four of these patients showed early
recurrence and/or metastatic disease, resulting in shortened survival (they died
within one year after surgery). The incidence of thrombocytosis increased to
12.2% and 20.6%, respectively, in patients with stage III and IV disease. The
overall survival rate of patients with thrombocytosis was lower than those
without thrombocytosis in the stage II and III disease groups, but this difference
disappeared in patients with stage IV cancer who did poorly regardless of their
platelet count. We concluded that thrombocytosis at diagnosis indicates
adverse clinical outcome in colorectal cancer patients with stage II or III
disease. This observation is especially intriguing in stage II patients because
the clinical management of these patients is controversial. If our data are
confirmed in larger studies, stage II colon cancer patients with thrombocytosis
should be upstaged and treated as stage III/IV disease patients.
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Introduction
Platelets play important roles in hemostasis, immunity and inflam-
mation1. Cancer is often associated with thrombocytosis2. Throm-
bocytosis was reported as a poor prognostic indicator in many 
types of cancers including lung cancer3, renal cell carcinoma4 and 
gynecological cancers5. A positive correlation between the depth of 
tumor invasion and platelet counts was demonstrated in a gastric 
cancer study, and thrombocytosis served as an adverse prognostic 
factor in clinical outcome in gastric cancer patients6. Recent studies 
have shown that thrombocytosis in cancer may be correlated with 
serum cytokine levels that stimulate thrombopoiesis. For example, 
elevated plasma levels of IL-6 and thrombopoietin were reported in 
ovarian cancer patients5.
Colon cancer is a leading cause of cancer-related death in devel-
oped countries (http://seer.cancer.gov/statfacts/html/colorect.html). 
A significant portion of patients receiving potentially curative resec-
tion dies within five years of diagnosis7. Since both chemo- and 
radiation therapies cause very significant side-effects, it is critical 
to define reliable prognostic factors to identify patients who might 
benefit from more aggressive adjuvant treatment options. The prog-
nostic role of thrombocytosis in colorectal cancer patients has not 
been fully investigated, although there are some reports supporting 
the negative impact of thrombocytosis on the survival of patients 
with colorectal cancer8,9.
In this study, the aim was to analyze the association between plate-
let count at diagnosis or pre-surgery and cancer stage, and to deter-
mine the prognostic significance of thrombocytosis in patients with 
colorectal cancer.
Patients and methods
After approval by the Monmouth Medical Center Institutional 
Research Review Board (IRB Study # 213-041), the medical 
records of 310 consecutive colorectal cancer patients who under-
went biopsy (47 patients), surgical resection and/or neoadju-
vant treatment (263 patients) at our institution between 2004 and 
2013 were retrospectively reviewed. The patient cohort included 
62 patients with in-situ or stage I disease, 78 patients at stage II, 
98 patients at stage III, 34 patients at stage IV, and 38 patients with 
biopsy diagnosis only (stage could not be determined). The mean 
age of the patients was 69.9±12.7 years (range = 32 to 98 years). 
The data gathered included platelet counts, tumor location, histo-
logical type, lymph node metastasis, depth of tumor invasion (T), 
presence or absence of distant metastasis, and survival time.
Pre-operative platelet counts were collected from our Laboratory 
Information System (LIS), and thrombocytosis was defined as 
platelet count ≥ 400 × 103/μl. After resection of the tumor, all speci-
mens were histologically examined by a pathologist and the patho-
logical TNM stage was determined according to the American Joint 
Committee on Cancer, 7th edition. Stage I and II cancers are lymph 
node negative (N0) whereas stage III is defined by the presence of 
lymph node metastasis. Patients with distant metastatic disease are 
classified as stage IV.
Survival data were provided by the Cancer Registry at the Leon Hess 
Cancer Center, Monmouth Medical Center. All calculations were 
made using R version 2.15.0 and packages “beeswarm”, “survplot”, 
“survival” and “stats”. Survival curves were generated using the 
Kaplan-Meier method. Hazard ratios with 95% confidence intervals 
were obtained using Cox proportional hazards regression. Long-
rank test was used for the analysis of significance.
Results
The characteristics (including age, gender, pT stage, tumor dif-
ferentiation and platelet count) of the patients in our study cohort 
are shown in Table 1. Of the 310 patients with colorectal cancer, 
25 (8.1%) had thrombocytosis at diagnosis or pre-surgery with the 
highest incidence detected in stage IV patients (20.6%) [Table 2]. 
Importantly, none of the 57 patients with stage I carcinoma had 
elevated platelet count. Although the mean platelet count increased 
with the depth of invasion (pT), it remained within the normal limits 
in all patients groups (pT1 to pT4) [Figure 1]. Mean platelet counts 
(×103/μL) were 216±71 (pT1), 252±83 (pT2), 274±109 (pT3), and 
291±104 (pT4); this increase was significant at P = 0.001. By con-
trast, there were no significant differences in thrombocytosis with 
regard to gender, age, location, or tumor differentiation (data not 
shown).
The combined incidence of thrombocytosis in stage III and IV dis-
ease was 14.4%. Stage II disease had the lowest incidence (6.4%) 
Table 1. Patient characteristics.
Number (%)
Total 310
Gender
   Male 151 (48.7%)
   Female 159 (51.3%)
Age 69.9±12.7 yearsa
Pathologic category of primary tumor (pT)b
   pTis 5 (1.6%)
   pT1 17 (5.5%)
   pT2 60 (19.4%)
   pT3 137 (44.2%)
   pT4 44 (14.2%)
   pTx (unclassified) 47 (15.2%)
Gradec
   well differentiated 42 (13.5%)
   moderately differentiated 149 (48.1%)
   poorly differentiated 67 (21.6%)
   unclassified 52 (16.8%)
Platelet count (×103/µL)
   ≥ 400 25 (8.1%)
   < 400 285 (91.9%)
a: Data presented as mean ± SD; b: staging according 
to AJCC Cancer Staging Manual 7th Edition); c: Grading 
according to WHO grading system
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Table 2. Incidence of thrombocytosis in each stage of colorectal cancer.
Number of 
cases with 
thrombocytosis
Number of 
cases without 
thrombocytosis
Total 
number 
of cases
% of 
thrombocytosis
Stage 0 0 5 5 0.0
Stage I 0 57 57 0.0
Stage II 5 73 78 6.4
Stage III 12 86 98 12.2
Stage IV 7 27 34 20.6
Stage X 
(unclassified) 1 37 38 2.6
Overall 25 285 310 8.1
*Stage IV and III 
combined 19 113 132 14.4
Note: There are 403 cases in our data pool. 310 cases were diagnosed as colon cancer among the 
321 cases with available platelet counts (82 cases without platelet counts). 11 non-colorectal cancer 
cases including 5 cases labeled as “appendix” and 6 cases labeled as “not colon cancer” were taken 
out of the pool.
Figure 1. Mean platelet count according to the depth of tumor invasion. The mean platelet count of patients with pT1, (216±71) × 103/µL 
is significantly lower than patients with pT4 (291±104) × 103/µL, P = 0.001.
and stage IV cancer showed the highest incidence of elevated 
platelet count (20.6%) [Table 2]. The overall survival of patients 
with stage I to stage III colorectal cancer with thrombocytosis was 
significantly lower than those without thrombocytosis [Figure 2]. 
Although patients with Stage IV carcinoma had the highest preva-
lence of thrombocytosis, these patients did uniformly poorly and 
the difference in survival was no longer observed in patients with 
or without elevated platelet count (not shown). Patients with throm-
bocytosis (PLT ≥ 400 × 103/μL) at stage I to stage III had a hazard 
ratio of 2.2 compared to the patients without thrombocytosis (PLT 
< 400 × 103/μL) as shown in Figure 2.
Dataset 1. Data of thrombocytosis in colon cancer patients
http://dx.doi.org/10.5256/f1000research.4856.d33371
This data set contains the medical records of patients diagnosed 
with colon cancer at the Monmouth Medical Center between 2004 
and 2013.
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Discussion
It was noted more than 100 years ago that thrombocytosis is often 
seen in patients with malignant diseases. Indeed, thrombocytosis 
correlates with both worse disease free survival and shortened over-
all survival in patients with ovarian cancer3, and worsens overall 
survival in patients with gastric cancer (reviewed in 10). The prog-
nostic significance of thrombocytosis in colorectal cancer, however, 
remains controversial11, although the majority of literature suggests 
a negative impact of thrombocytosis on the survival of patients with 
colorectal cancer8,9.
In the present study, we identified a mild, T stage-dependant 
increase in mean platelet counts in patients with colorectal carci-
noma that reached statistical significance when comparing T1 to 
T4; however, the mean platelet count remained within the normal 
limits in the whole patient cohort. Importantly, thrombocytosis was 
more common among patients with advanced disease: its preva-
lence increased from 6.4% in stage II to 20.6% in stage IV cancer 
patients. Our data are comparable to those reported in the literature 
(12.1–13.9%;6,7).
In our study, thrombocytosis showed adverse prognostic signifi-
cance in patients with stage I to stage III colorectal carcinoma; this 
was no longer apparent in patients with stage IV disease, presuma-
bly because these patients did poorly regardless of the platelet count.
Probably the most intriguing observation of our study is the 
fairly uniformly dismal clinical outcome of stage II patients with 
thrombocytosis (five out of 78 patients): four of these five patients 
did very poorly (they died within a year) and the fifth was lost 
to follow-up. We suspect that these cases might represent stage 
III/IV cases misclassified as stage II due to false negative lymph 
node examination. At present, the National Comprehensive Cancer 
Network guidelines do not recommend routine administration 
of adjuvant chemotherapy to stage II colorectal cancer patients 
whose cancer was completely resected12. If our data are confirmed 
in future larger studies, stage II colorectal cancer patients with 
thrombocytosis should be upstaged and treated clinically as stage 
III/IV.
The molecular mechanisms underlying thrombocytosis in cancer 
patients are incompletely understood. Recently, plasma levels of IL-6 
and thrombopoietin were found to significantly correlate with plate-
let counts in ovarian cancer patients. Indeed, silencing of the IL-6 
and thrombopoietin genes markedly abrogated thrombocytosis (and 
halted tumor progression) in a mouse model of epithelial ovarian 
cancer5. These findings are promising because an anti-IL-6 agent 
(siltuximab) has already been approved by the United States Food 
and Drug Administration (FDA) to treat patients with Castleman’s 
disease (http://www.cancer.org//cancer/new/fda-approves-sylvant-
siltuximab-for-castleman-disease). Another series of study showed 
that immobilized platelets support human colon carcinoma cell 
tethering, rolling, and firm adhesion under dynamic flow conditions 
in colon cancer cell lines, suggesting a role of platelets in hema-
togenous dissemination of tumor cells in colorectal cancer13. Taken 
together, these studies imply that inhibition of thrombocytosis may 
represent a potential novel target in cancer therapy.
In summary, thrombocytosis appears to herald adverse clinical out-
come in patients with stage II and III colorectal carcinoma. We sug-
gest that elevated platelet count may identify a subset of patients 
with stage II colon cancer who could benefit from close follow-up 
and aggressive adjuvant therapy.
Data availability
F1000Research: Dataset 1. Data of thrombocytosis in colon cancer 
patients, 10.5256/f1000research.4856.d3337114
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Figure 2. Overall survival plots of patients with stage I to stage 
III colorectal cancer according the preoperative platelet counts. 
Patients were allocated into two groups: with thrombocytosis, PLT 
≥ 400 × 103/µL (labeled as Exceeds) and without thrombocytosis) 
PLT < 400 × 103/µL (labeled as Normal). The patients with 
thrombocytosis have a hazard ratio of 2.2 compare to the patients 
without thrombocytosis (P<0.05).
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Version 1
 06 October 2014Referee Report
doi:10.5256/f1000research.5184.r6229
 Judit Moldvay
Department of Pulmonology, Semmelweis University, Budapest, Hungary
It is an interesting work providing new information on the issue of thrombocytosis in colon cancer patients.
It contains relevant clinicopathologic parameters, however, there is no data on ethnicity, smoking habits,
inflammatory processes, comorbidities, or medications of the studied patients, all which might have
impact on platelet count .(Msaouel , 2014)et al.
The main factors that can influence the platelet count should at least be discussed.
In Figure 1. the Authors discussed the mean platelet count according to the depth of tumor invasion.
Although it might change statistically significantly, the mean platelet count remains much within the
normal range, therefore, the conclusion that “… we identified a mild, T stage-dependant increase in mean
platelet count …” is not well-founded. 
One of the most critical aspects of the investigation is the number of patients, especially in stage II, as
disproportionately firm conclusions have been drawn regarding correlation between overall survival and
thrombocytosis on the basis of only four patients with thrombocytosis in stage II.
Another weakness of the study is the lack of information on the precise localizations of the primary
tumors, as this in itself may be of prognostic value, e.g.  . Majek (2012)et al. 
Although neoadjuvant treatment has been mentioned, it was not discussed in details, similarly, adjuvant
treatments in advanced cases were not detailed either.These issues should be discussed in the
"Discussion".
In Figure 2. the value of HR is not in accordance with the HR in the legend.
In the 4  line of the Discussion there is a mistake with the Ref. 3., this – most probably – is the Ref. 5.
Similarly, in the 18  line of the Discussion the Ref. 6. – most probably – is the Ref. 8.
In conclusion, this study yielded clinically very interesting results that might have therapeutic
consequence, however, these results need to be confirmed in a much larger cohort of colorectal patients.
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All in all, in my opinion this manuscript is acceptable for indexation, but only after corrections and
completions based on the above mentioned comments.
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard, however I have significant reservations, as outlined
above.
 No competing interests were disclosed.Competing Interests:
Author Response (  ) 13 Oct 2014Member of the F1000 Faculty
, Department of Pathology, Monmouth Medical Center, USAArpad Szallasi
Whereas we share some of the reservations of the referee, we would like to point out that this is an
Observational Study and not a full report. We believe that despite the limitations of this study, this
is an interesting observation with potential implications for patient management. That said, we
wholeheartedly agree with the referee that "these results need to be confirmed in a much larger
cohort of colorectal patients." 
Changes done in response to points raised by the referee in the revised MS include:
Our study has a number of limitations such the lack of data on ethnicity, smoking habits,
comorbidities, or medications: this is now clearly stated in Patients and Methods. We
believe that such a detailed, multifactorial analysis would surpass the confines of a
preliminary Observational Report. Of note, the patient database is available for review for
the interested reader (please follow link under Reference 14 to "data source").
 
The most common causes of reactive thrombocytosis are now briefly listed in the
Introduction.
 
The statement between platelet count and depth of invasion has been toned down - the
reference to significance has been eliminated.
 
As emphasized in the MS, our conclusions are preliminary and are based on a limited
number of patients. It is our hope that our findings will be confirmed (or refuted) based on a
much larger patient cohort. 
 
The localization of the primary tumor (right-sided versus left-sided) seems to have no impact
on the presence or absence of thrombocytosis: both groups had an incidence of ~7%. This
is now clearly stated in Results. 
 
References have been corrected.
 NoneCompeting Interests:
 14 August 2014Referee Report
doi:10.5256/f1000research.5184.r5655
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 Ioannis A. Voutsadakis
Medical Oncology, Sault Area Hospital, Ontario, Canada
This is an interesting retrospective study of an extensive series of colorectal cancer patients and authors
are to be congratulated on undertaking this academic endeavour. Nevertheless there are several points
that need to be addressed. A major concern is that all stages of the disease have been included. In
general a comparison between stage I and IV, for example, has no meaning clinically and the only
statement that one can make is that thrombocytosis is more common. Another major concern is that no
multivariate analysis is done or presented.
Some other specific points:
The title mentions specifically stage II disease (as the authors probably recognize the importance
of prognostic factors in this sub-group for therapeutic decisions) but no statistical comparison is
offered anywhere in the article. In any case the number of patients with thrombocytosis in this
group (5) is prohibitive for definite conclusions.
 
In the last line of the Abstract and in the Discussion it should be: “ ” or even bettertreated as stage III
“ ” (stage IV patients are treated with palliative intent).considered for adjuvant chemotherapy
 
Data on tumor grade and location have been collected (dataset) but not summarized or presented
in the article. It would be of particular interest to present and include in an eventual multivariate
analysis tumor location (right versus left from the splenic flexure versus rectal).
 
In Patients and methods the normal range of platelets in authors’ institution should be mentioned.
 
In the Results it would be interesting to provide the mean and SD of the platelet number in the 2
groups (normal and thrombocytosis).
 
In fig. 2 there is a discrepancy between HR and p values in the body and the legend. In addition the
numbers at risk do not match. Is that a mistake in calculations or data missing? Authors should
address this.
 
In the 4  line of the 1  paragraph of the Discussion” the reference does not seem to be correct.
Same with reference 6 in the 2 paragraph.
 
In the discussion on metastatic patients - this is an over-simplification. If any useful comparison is
to be made, other data have to be entered in the equation such as oligometastatic versus
polymetastatic disease and treatments.
 
Treatments should be mentioned. For example have all stage III patients received adjuvant
chemotherapy? And have any of the stage II patients received any such treatment?
 
In the 4  paragraph of the Discussion the explanation of “ ” isfalse negative node examination
improbable as there is no reason to suspect that such false negative occurs more commonly in
patients with thrombocytosis. Instead a difference in biology as briefly discussed in the next
paragraph is more probable.
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
th st
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I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard, however I have significant reservations, as outlined
above.
 No competing interests were disclosed.Competing Interests:
Author Response (  ) 13 Oct 2014Member of the F1000 Faculty
, Department of Pathology, Monmouth Medical Center, USAArpad Szallasi
We are grateful for the referee for his thoughts in making this a better MS. Whereas we agree with
most of the reservations of the referee, we would like to point out that this is an Observation Study,
and not a full report. We believe that despite the limitations of our study, our conclusions are sound
and (if confirmed) may have important implications for patient management.
Major changes done in response to points raised by the referee include:
We agree with the referee that the small number of patients (5) in the stage II group
precludes a definitive conclusion; this is now clearly stated in the MS. Again, this is an
Observational Study within the confines of our hospital database on colorectal carcinoma
patients.
 
Both the Abstract and the Discussion have been modified as suggested by the referee
("treated as stage III" has been changed to "may be considered for adjuvant
chemotherapy").
 
The multivariate analysis with special regard to the location of the tumor (right-sided versus
left-sided) in now detailed in the Results.
 
The normal range of platelets at our Institution (150 to 400 K/ul) is now provided in the MS.
 
The mean +/-SD of the platelet counts in the two patient groups (with and without
thrombocytosis) is now provided in Results.
 
Indeed, there is a discrepancy between the body of the text and Figure 2 with regard to the
patient numbers; this should have been addressed before to avoid any confusion. As clearly
stated now in Patients and Methods, our database included 310 patients. Of these patients,
our Cancer Registry had long-term survival data on 253 patients (hence the discrepancy):
the remaining 57 patients most likely decided to seek treatment at a different facility.
 
References have been corrected.
 
Discussion on metastatic patients has been modified.
 
Unfortunately, our Cancer Registry has no full details on chemotherapy regimens (some of
our patients receive chemotherapy in a private practice setting).
 
The reference to "false negative node examination" has been eliminated.
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